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OBJECTIVES The goal of this study was to evaluate the dose-dependency of morphometric changes in the
coronary arterial wall after radioactive stenting.
BACKGROUND Radioactive stents have been found to reduce intrastent intimal hyperplasia (IIH) but lead to
a characteristic type of restenosis occurring predominantly at the stent edges.
METHODS Fifteen patients underwent intravascular ultrasound (IVUS) examination after implantation
of a P-32 radioactive stent and at the six-month follow-up. The post-stent IVUS
measurements on seven predefined locations of each lesion were subjected to a computer
algorithm for the development of dose-volume histograms (DVH). Thus, we derived the
radiation doses delivered to at least 10% and 90% of the adventitia (DV10, DV90). The IIH
and vascular remodeling at follow-up were correlated with the doses in each segment.
RESULTS The IIH was most pronounced at the stent edges and lowest in the stent-body, whereas we
detected a significant expansive remodeling within the stent body. The delivered doses
correlated with a decreased IIH (r  0.52, p  0.001 for DV10 and r  0.62, p  0.001 for
DV90) and with expansive remodeling (r  0.48, p  0.009 for DV10 and r  0.50, p 
0.006 for DV90). A DV10 90 Gy or a DV90 15 Gy reduced IIH and induced expansive
remodeling. Plaque growth was not reduced by radioactive stents.
CONCLUSIONS The DVH analysis reveals a dose-dependent increase of external elastic lamina area behind
radioactive stents, whereas plaque growth is not reduced but inverted into an outward
direction from the stent. A DV10 90 Gy or a DV90 15 Gy results in a beneficial
long-term outcome after radioactive stenting. (J Am Coll Cardiol 2002;39:400–7) © 2002
by the American College of Cardiology
Intravascular brachytherapy has become a promising inter-
ventional approach to reduce the restenosis rate after coro-
nary interventions. Its therapeutic effect is most probably
due to the prevention of the proliferation and migration of
smooth muscle cells and myofibroblasts from the media
and/or the adventitia to the intima (1). The devices used so
far include radioactive wire or seed sources, radioactive
stents and radioactive liquid-filled balloons. However, the
restenosis rates of intracoronary brachytherapy differ from
study to study, depending on the source and the protocol
(2). All devices (and in particular beta-particle-emitting
stents) are limited by a peculiar type of restenosis at the
margins of the interventional length, termed “candy-
wrapper” or edge-effect (3). The clinical experience empha-
sizes the importance of dosimetry because underdosing will
be ineffective in reducing restenosis (4) or may even stim-
ulate cell growth (5), whereas overdosing may cause vessel
damage, such as aneurysm development (6). We recently
developed a computer algorithm to analyze the dose distri-
bution in a given zone of the vessel wall by applying
dose-volume histograms (DVHs) (7). Dose-volume histo-
grams, which describe the distribution of the irradiated
tissue volume with respect to dose, are widely utilized for
treatment planning in radiotherapy (8). Explicit values of
dose-volume parameters can be extracted from the DVH
data, for example, the dose delivered to at least a given
percentage of the volume. In order to calculate DVHs, it is
necessary to obtain information on the geometry of the
vascular cross-sections. Intravascular ultrasonography
(IVUS) is a well-established technique providing this infor-
mation by tomographic imaging of the vessel wall. The
present study was performed to test the value of IVUS-
derived DVHs for determining the dose-dependency of
intimal hyperplasia and vascular remodeling after implanta-
tion of radioactive P-32 stents.
METHODS
Patients. All patients were prospectively enrolled in the
Vienna P-32 Dose Response study, which was designed to
test the safety and efficacy of beta-particle-emitting
phosphorus-32 BX stents (Isostent, Belmont, California)
with an initial activity up to 888 kBq (24 Ci) in patients
with either de novo lesions, in-stent restenoses or restenoses
after balloon dilation (9). The stents were available in a
length of 15 mm and a nominal diameter of 3.0 mm or
3.5 mm in the expanded mode. The study was performed in
accordance with the Helsinki Declaration of 1964, as
revised in 1989, and was approved by the Medical Ethics
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Committee of the University of Vienna. All patients gave
written informed consent for their participation. From
January to May 1999, 36 patients underwent implantation
of one or two P-32 impregnated BX stents per lesion.
For this dose-response analysis we included only patients
with de novo lesions without significant calcification that
were treated with a single stent. In-stent restenoses (n  6,
16.7%) or severely calcified lesions (n  3, 8.3%) were
excluded because the shielding effect from previously im-
planted stents or calcification cannot be exactly estimated at
this time without histologic analysis. Furthermore, we
excluded patients with more than one stent per lesion (n 
8, 22.2%) in order to eliminate uncertainties resulting from
differences in the relative position of the stents (separate,
abutting or overlapping). After the exclusion of patients for
whom incomplete follow-up or IVUS documentation was
available (n  4, 11.1%), 15 patients were analyzed for this
study.
Coronary intervention and IVUS imaging. Biplane cor-
onary angiography was performed by using the Judkins
technique. Before the intervention, the patients received
250 mg acetylsalicylic acid and 10,000 IU heparin intrave-
nously. During the procedure, the activated clotting time
was measured and maintained 300 s. Optimal stent
deployment was guided by IVUS (Boston Scientific Corp.,
Sunnyvale, California) under fluoroscopic control. Auto-
matic pullback of the catheter was performed (0.5 mm/s),
and images were recorded (s-VHS videotapes) for subse-
quent off-line analysis. After the intervention, the patients
were treated with acetylsalicylic acid (100 mg/day, indefi-
nitely) and ticlopidine (500 mg/day for 90 days). Coronary
angiography and IVUS were performed in the same way at
the six-month follow-up.
Quantitative IVUS. Data on reproducibility of our IVUS
measurements have been published elsewhere (10). For
geometry reconstruction, IVUS images after stent implan-
tation and at follow-up were analyzed off-line by an expe-
rienced observer. In order to superimpose the dose-
distribution grid on a longitudinal vessel geometry model,
seven sections were selected by modifying a previously
published method of serial IVUS analysis (11). Given the
constant pull-back velocity of 0.5 mm/s, we determined the
following measurement points: a cross-section 2.5 mm
distal of the stent (distal peri-stent) (A), the distal stent edge
(B), the first quarter (C), the center (D) and the third
quarter of the stent (E), the proximal stent edge (F) and a
cross-section 2.5 mm proximal of the stent (proximal
peri-stent) (G) (Fig. 1). The measured frame was consid-
ered to be representative for the corresponding total section
volume. The lumen area (LA) and the total vessel area were
measured in end-diastolic frames by manually tracing the
leading edge of the intima and the external elastic lamina
(EEL), respectively. In our study, the EEL was visible and
traceable in all cases. Plaque area (PA) was defined as the
intimamedia area and was calculated as EEL area LA.
Plaque growth was determined as the difference between
PA at follow-up and postintervention (PA). For the stent
segments (B to F), intrastent intimal hyperplasia (IIH) was
defined as stent area at follow-up  LA at follow-up. The
extent of vascular remodeling was determined by EEL
(EEL at follow-up  EEL after stent).
Abbreviations and Acronyms
DVH  dose-volume histogram
DV10  the dose of radiation delivered to at least 10%
of the adventitial volume
DV90  the dose of radiation delivered to at least 90%
of the adventitial volume
EEL  external elastic lamina
IIH  intrastent intimal hyperplasia
IVUS  intravascular ultrasound
LA  lumen area
LDR  low-dose rate
PA  plaque area
Figure 1. Schematic drawing of a stented vessel segment. For localization of the cross-sections, see the text. Atherosclerotic plaque was defined as the
difference between the lumen area (LA) and the external elastic lamina (EEL) area. Intrastent intimal hyperplasia was defined as the difference between
the stent area and the LA at follow-up.
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Dosimetry. The DVH calculations used in our study are
based on the dose distribution around the stent as calculated
by Janicki et al. (12) for the source immersed in water as
adapted to the design of the BX stent. The underlying dose
map was chosen on the basis of the nominal stent diameter
(3.0 mm and 3.5 mm) and the activity at the time of
implantation but adapted to the real dimension of the stent
once implanted as delineated by IVUS. The algorithm used
in the present calculation model has been described in detail
elsewhere (7). Briefly, the underlying dose map is based on
the stent design and the initial activity. The algorithm used
in our approach also includes the actual geometry of the
stent within the vessel wall and its position related to the
adventitia, the assumed target volume. The actual dose
distribution within the adventitia is derived by determina-
tion of the actual distances between the stent surface and a
representative amount of points within the target volume.
This incorporates deviations from the nominal circular
shape of the stent and vessel wall geometry. In the present
work, all calculated doses are given as the cumulative dose
received within 28 days after stent implantation according
to the recommendations of the American Association of
Physicists in Medicine (13).
Histogram calculation. We assessed the dose distribution
within the adventitia, presuming a thickness of 0.5 mm
from the EEL contour (14). The digitalization of an
individual IVUS section generates a two-dimensional ma-
trix containing a polygon of the vessel lumen contour and
the EEL contour with one matrix cell (voxel) representing a
square of approximately 40  40 m. The third dimension
is obtained by including the length of the respective seg-
ment (3.0 mm or 2.5 mm) representing the Z-axis. A
computer algorithm developed in our laboratory using the
MATLAB 5.1 programming language (The MathWorks,
Inc., Natick, Massachusetts) calculates the dose in randomly
allocated voxels inside the target volume.
To calculate differential DVHs, the computer code
counts the number of those voxels receiving a dose within
specified equispaced dose intervals of 1 Gy. The cumulative
DVH, representing the percentage of the total target
volume receiving a dose greater than or equal to a given dose
is derived by a summation procedure of the differential
Figure 2. Cumulative dose-volume histogram of three segments from one patient receiving a radioactive stent. The ordinate represents the percentage of
target volume receiving at least the respective dose shown at the abscissa. The value of DV10 is marked by a circle and that of DV90 by a diamond. Note
the different decline of the curves in each segment resulting in a broad variety of delivered doses, especially of the dose of radiation delivered to at least 10%
of the adventitial volume, and a high cumulative dose in the central segments.
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DVHs (Fig. 2). In order to compare DVHs, the minimum
doses of radiation delivered to at least 10% and 90% of the
adventitial volume are presented (DV10, DV90). Whereas
DV90 accounts for the therapeutic effect of radiotherapy,
the higher values of DV10 determine the deleterious se-
quelae of irradiation. It should be noted that these values
cannot be compared with the respective dose delivered by a
temporary brachytherapy source because they refer to a
reference volume, not only to a reference point, and because
the radioactive stents have a much lower dose rate.
Statistics. Results are expressed as means  SEM. The
segmental data (LA, IIH, EEL, PA) on all patients were
compared by analysis of variance. We used an unpaired t test
in order to compare morphometric changes between high-
dose (DV1090 Gy, DV9015 Gy) and low-dose (DV10
90 Gy, DV90 15 Gy) groups. These doses do not
represent calculated threshold values but have been derived
from our raw data because the morphometric changes were
most evident in this range. Most protocols using intravas-
cular catheter-based brachytherapy employ a dose of ap-
proximately 15 Gy, which, therefore, is a familiar number to
most cardiologists. The threshold of DV10 has been fixed
sixfold higher than that of DV90. There are, of course,
differences in the biologic effect of low-dose rate (LDR)
and high-dose rate irradiation with the same cumulative dose,
as will be discussed later. The dose-response relationship was
tested by regression analysis; the variance stabilization of the
x-value was obtained by logarithmic transformation:
y  b0  b1.ln	x

In order to avoid the bias due to serial data being obtained
from the same patient, which would unwarrantedly increase
the number of observations, the data on the segments
displaying nonsignificant differences between the segments
were averaged, and the correlation between the greatest and
smallest segmental changes in intimal hyperplasia and EEL
versus radiation doses (DV10 and DV90) were calculated
(StatView 5.01, SAS Institute Inc, SAS Campus Drive,
Cary, North Carolina). Differences were considered signif-
icant when p value was 0.05.
RESULTS
Clinical data. Fifteen patients (14 male and 1 female,
mean age: 61.1 2.8 years) were included in this study. Ten
stents were implanted in the left anterior descending coro-
nary artery (66.6%), one (6.6%) in the left circumflex
coronary artery and four (26.7%) in the right coronary
artery. Five patients (33.3%) received a 3.0-mm stent and
10 patients (77.7%) received a 3.5-mm stent (mean 3.33 
0.2 mm). The average stent radioactivity at the time of
implantation was 426.24  34.0 kBq (11.52  0.9 Ci);
the mean dose within 0.5 mm from the stent surface in the
central plane was 107.9  8.3 Gy. Four of the 15 patients
(26.6%) had a significant angiographic restenosis 50%
diameter stenosis at follow-up. Ta
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Spatial description. The morphometric changes within six
months are tabulated in Table 1A. There was no significant
difference between stent area after implantation and at
follow-up, indicating minimal stent recoil. The DV10 and
DV90 increased progressively from the stent ends to the
center of the stent (Table 1B) as a consequence of the dose
distribution of the BX stent. The decrease in lumen area was
highest at the edges (p  0.029). The analysis of the EEL
showed a significant increase by up to 18% within the stent
(p  0.016), but no changes at the edge- and peri-stent
segments. Of note, the changes in total PA did not differ
between in-stent, edge and peri-stent segments; there was
even a trend towards an increase in the in-stent segments.
There was no correlation between any of the analyzed IVUS
parameters and the initial stent activity.
Dose-dependency of IIH. Intrastent intimal hyperplasia
(but not total PA) increased at the stent edges and decreased
within the stent body (Fig. 3). Regression analysis between
IIH and DV10 and DV90, respectively, revealed a signifi-
cant logarithmic correlation (DV10: r  0.516, y  9.90–
1.82 ln[x], p  0.0058; DV90: r  0.617, y  4.66–1.03
ln[x], p  0.0005) (Fig. 4).
Dose-dependency of vascular remodeling. The EEL was
unchanged at the stent edges and increased markedly
around the stent body (Fig. 3). Regression analysis demon-
strated a significant logarithmic correlation between the
EEL (smallest response in B and F and greatest response in
segments C, D and E) and DV10 (r  0.476, y  10.97
 2.53 ln[x], p  0.009) and DV90 (r  0.498, y  2.65
 1.13 ln[x], p 0.006) (Fig. 5). The observed constriction
at the peri-stent segments was not significant compared to
the other segments.
Morphometric differences between high-dose and low-
dose segments. Interstent intimal hyperplasia was sig-
nificantly reduced in the segments that received a DV90
15 Gy (0.8  0.3 mm2 vs. 2.19  0.2 mm2, p  0.001)
or a DV10 90 Gy (1.10  0.3 mm2 vs. 1.93  0.3 mm2,
p  0.035). The EEL was also more pronounced in
segments receiving a DV90 15 Gy (1.88  0.4 mm2 vs.
0.12  0.4 mm2, p  0.001) or a DV10 90 Gy (1.57 
0.3 mm2 vs. 0.42  0.4 mm2, p  0.032). However, the
changes in PA did not differ between the DV90 (2.31 
0.4 mm2 vs. 2.70  0.3 mm2, p  0.524) and DV10 (2.35 
0.4 mm2 vs. 2.66  0.3 mm2, p  0.436) groups.
DISCUSSION
This study is the first to determine a dose-dependency of
IIH and expansive remodeling after implantation of radio-
active stents in human arteries by using IVUS-derived
DVHs. Accordingly, the lumen at the stent edges is
obstructed due to insufficient vessel expansion consecutive
to lower doses in the presence of continuously growing
neointima.
Figure 3. Comparison between the delivered dose at 10% and 90% of the
adventitia (DV10, DV90), the reduction of the intimal hyperplasia and the
increase in external elastic lamina (EEL) area. Note the increased intrastent
intimal hyperplasia (IIH) at the stent edges. These segments absorbed
lower doses than the stent body but higher doses than the peri-stent
segments, which exhibit less intimal hyperplasia. Expansive remodeling
occurs within the stent body but not at the edges and the peri-stent
segments.
Figure 4. Logarithmic correlation between intrastent intimal hyperplasia (IIH), the dose of radiation delivered to at least 10% of the adventitial volume
(DV10) and the dose of radiation delivered to at least 90% of the adventitial volume (DV90).
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Advantage of DVHs in vascular brachytherapy. Previous
investigations of radioactive stents (15,16) did not integrate
the actual geometry of the treated vessel, the three-
dimensional expansion of the adventitia and the apposition
of the stent into their models nor did they assess the entire
interventional length. Thus, it was impossible to determine
a clear dose-response relation. The initial stent activity and
the dose within 0.5 mm from the stent surface in the central
plane alone did not correlate with morphologic changes,
which creates the need for a more careful assessment of
doses delivered to a defined volume. The application of
DVHs, which have recently been adapted to intravascular
brachytherapy (14,17,18) requires adjustment for the differ-
ences in nature between the temporary brachytherapy
sources and the permanently implanted LDR sources like
radioactive stents. We have recently developed an IVUS-
based computer algorithm for DVHs, which accounts for
the considerations mentioned in the previous text so that
the dose delivered to a certain vessel layer over any given
time can be calculated (7). This model allows the establish-
ment of a radiobiologic relationship between the delivered
dose and the vascular response to LDR radiation.
Morphometric changes after radioactive stenting. Our
study reveals an inverse logarithmic correlation between the
delivered dose and the IIH. Interestingly, we found a
changing pattern of vascular remodeling along the analyzed
segment over six months after the intervention; the mean
increase in EEL area, which also showed a direct logarith-
mic correlation with the delivered dose, was about 15%
within the stent, whereas it was only 6.6% at the edges and
even slightly negative (1.3%) at the peri-stent segments.
The amount of intimal formation alone did not increase by
30%, even in the edge segments, which is too low to result
in a significant stenosis. However, even in the stent seg-
ments without angiographic restenosis, PA increased by up
to 72% due to a pronounced expansive remodeling. Thus,
our study is the first to suggest a predominant role of
vascular remodeling in the vascular response to radioactive
stenting. Whereas vessel enlargement after temporary irra-
diation has been observed in both animals and humans (2),
Kay et al. (19) did not detect an increased EEL area after
radioactive stenting. This contrast may be explained by a
lower activity of the stents used in their analysis (444 kBq)
because we have shown that a DV90 15 Gy or a DV10
90 Gy are ineffective in inducing vessel expansion. How-
ever, our data confirm the findings of Albiero et al. (20) who
observed constrictive remodeling in peri-stent segments.
The lack of expansive remodeling at the stent edges in the
presence of constant intimal hyperplasia leads to the devel-
opment of the “candy-wrapper” stenosis. Thus, the positive
effect of vascular brachytherapy seems to depend on a
significant increase in vessel size. The long-term outcome of
radioactive stenting, therefore, is uncertain even after a
satisfactory six-month result because expansive remodeling
has been shown to be associated with unstable coronary
syndromes (10).
Surprisingly, plaque growth was not reduced along the
analyzed section. This phenomenon may be explained by
the image of an “electron fence” created around the radio-
active stent, which does not reduce cell proliferation but
prevents cells from passing the plane of the stent struts (21).
Consequently, the proliferating cells may accumulate in the
abluminal vessel layers, thus increasing the vessel thickness
without obstructing the lumen. Farb et al. (22) found a
thickened adventitia in the presence of an increased inflam-
matory response and a matrix-rich intima in rabbit iliac
arteries treated with radioactive stents. Furthermore, it has
been shown that irradiated and, therefore, quiescent smooth
muscle cells continue to synthesize elastin, which serves as a
chemoattractant for monocytes (23). Another explanation
may be drawn from the heterogeneity of vascular smooth
muscle cells (24). It is conceivable that subpopulations with
longer cell cycle times are less affected by LDR radiation
from the radioactive stent due to a different radiosensitivity
(25,26).
Dose-response relation of the edge effect. Our study
demonstrates a logarithmic response of the vessel to the
delivered doses. Considering the hypotheses described in
Figure 5. Logarithmic correlation between expansive remodeling ( external elastic lamina [EEL]), the dose of radiation delivered to at least 10% of the
adventitial volume (DV10) and the dose of radiation delivered to at least 90% of the adventitial volume (DV90).
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the previous text, neointimal hyperplasia and vascular re-
modeling are coupled together and, therefore, should have
the same dose-dependency; if the delivered dose is insuffi-
cient to induce expansive remodeling, IIH may develop. By
DVH-analysis, we estimated a DV10 above approximately
90 Gy or a DV90 above approximately 15 Gy to result in a
beneficial six-month outcome of radioactive stenting. This
finding is more pronounced for DV90 because it refers to a
larger amount of the target volume. Due to the steep
dose-decline of the beta-particle-emitting stents, the DV90
delivered to the edges is only one-fifth of that within the
stent center. These values are far below the calculated
threshold to induce expansion so that the continuously
growing neointima can significantly obstruct the lumen.
There are, of course, differences in the biologic effect of
low-dose and high-dose irradiation with the same cumula-
tive dose, as discussed previously. Therefore, the derived
values may not be applicable to different treatment devices
without further adaptation.
Study limitations. This analysis was retrospectively per-
formed on a limited number of patients, which results in an
only moderate correlation between the delivered dose and
the vascular response. Furthermore, patients in whom the
IVUS catheter could not be advanced safely were excluded.
Thus, the restenosis rate in this selected group of patients
(26.6%) is markedly lower than it is in the total patient
cohort (42.9%) (9). However, the strict inclusion criteria of
this analysis allowed the exact determination of the deliv-
ered doses without any impairment by vessel calcification,
stent overlapping or side branches.
Intravascular ultrasound cannot distinguish between me-
dia and adventitia. Thus, we do not know which vessel layer
was responsible for the increase in EEL observed in our
study.
The determined doses are not directly measured but are
derived from DVHs in an IVUS-defined target volume.
The values are based on the dose distribution of P-32 with
its high dose gradient, the activity at the time of the
implantation and the vessel geometry as determined by
IVUS. It is quite possible that the plaque composition has
an impact on the dose absorption that cannot be taken into
account appropriately at the moment.
The three-dimensional dose map that we used is origi-
nally based on the presumption of a circular cross-section of
the stent (12). However, the cross-section of human vessels
is often elliptic rather than circular. Additionally, the
atherosclerotic plaque impairs the deployment of stents, so
that they may not be fully expanded to their nominal
diameter. Since there are only minimal differences between
the calculated nominal and the actually measured stent
cross-section area, it appears reasonable to use this previ-
ously reported dosimetry. The algorithm used in our ap-
proach includes the actual geometry of the stent within the
vessel wall and its position related to the adventitia, the
assumed target volume.
Restenosis may also occur beyond a distance of 3 mm
from the stent edge. However, the dose delivered to this
zone is only minimal. Other factors might be responsible for
the development of restenosis in these sections. Therefore,
we excluded more remote segments from our analysis.
Hemodynamically significant restenosis is the result of
extreme neointimal proliferation. The number of patients
(4/15) who developed restenosis in our study was clearly too
small to perform relevant statistical analysis. Therefore, we
analyzed the continuous development of neointimal prolif-
eration and remodeling instead of the end point of binary
restenosis and could not determine dose differences between
patients with or without restenosis.
Conclusions. The implementation of DVH reveals a dose-
dependent increase of EEL area behind radioactive stents,
whereas the plaque growth is not reduced but inverted into
an outward direction from the stent. A calculated DV10
90 Gy or a DV90 15 Gy seem to have a beneficial effect
on the six-month outcome of radioactive stenting. The use
of isotopes with a lower dose fall-off (e.g., gamma emitters)
for the development of radioactive stents could increase the
DV90 in the peri-stent segments and might potentially
decrease the incidence of edge-restenosis.
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